Given the detailed information on Farapulse's development, the technology's specific workings, and firsthand accounts from the medical professionals involved, the article can be considered Well Sourced. It not only outlines the technological advancements in treating atrial fibrillation but also reflects on the regulatory and clinical trial processes involved in bringing such a medical device to market.